Advertisement

Biological Approaches to the Therapy of Lymphoproliferative Diseases

  • Kenneth A. Foon
Part of the Developments in Oncology book series (DION, volume 31)

Abstract

Progress has been made over the past 5 years toward the development of specific biological approaches to the treatment of cancer. The techniques of genetic engineering and mass cell culture and improved techniques in protein and nucleic acid sequencing have made available biologics as highly purified molecules. The most definitive investigations have been carried out with the various interferon (IFN) preparations, and it is clear that they are capable of inducing responses primarily in patients with certain types of lymphomas and leukemias. Recent monoclonal antibody data, while interesting, have not yet demonstrated that monoclonal antibodies are effective in the treatment of lymphoma/leukemia. Intensive investigations are currently under way in both of these areas of clinical research.

Keywords

Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Autologous Bone Marrow Monoclonal Antibody Therapy Human Leukocyte Interferon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Merigan TC, Sikora K, Breeden JH, Levy R, Rosenberg JA. 1978. Preliminary observations on the effect of human leukocyte interferon on non-Hodgkin’s lymphoma. N Engl J Med 299:1449–1453.PubMedCrossRefGoogle Scholar
  2. 2.
    Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA, Merigan TC. 1981. Follow-up observations on the effect of human leukocyte interferon on non-Hodgkin’s lymphoma. Blood 58:712–718.PubMedGoogle Scholar
  3. 3.
    Gutterman J, Blumenschein G, Alexanian R, et al. 1980. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93:399–406.PubMedGoogle Scholar
  4. 4.
    Sherwin SA, Knost JA, Fein S, et al. 1982. A multiple dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248:2461–2466.PubMedCrossRefGoogle Scholar
  5. 5.
    Quesada JR, Reuben J, Manning JR, Hersh EM, Gutterman JU. 1984. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310:15–18.PubMedCrossRefGoogle Scholar
  6. 6.
    Foon KA, Sherwin SA, Abrams PG, et al. Recombinant leukocyte A interferon: An effective agent for the treatment of advanced non-Hodgkin1s lymphoma. N Engl J Med, in press.Google Scholar
  7. 7.
    Foon KA, Bottino GC, Abrams PG, et al. Recombinant leukocyte A interferon is not an effective agent for the treatment of advanced chronic lymphocytic leukemia. Am J Med, in press.Google Scholar
  8. 8.
    Bunn PA, Foon KA, Ihde DC, et al. 1984. Recombinant leukocyte A interferon: An active agent in advanced cutaneous T cell lymphoma. Ann Intern Med 101:484–487.PubMedGoogle Scholar
  9. 9.
    The non-Hodgkin’s lymphoma pathologic classification project. National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphoma. Summary and description of a working formulation for clinical usage. Cancer 49:2112–35, 1982.CrossRefGoogle Scholar
  10. 10.
    Oldham RK. 1983. Monoclonal antibodies in cancer therapy. J Clin Oncol 1(9):582–590.PubMedGoogle Scholar
  11. 11.
    Levy R, Miller RA. 1983. Tumor therapy with monoclonal antibodies. Fed Proc 42:2650–2756.PubMedGoogle Scholar
  12. 12.
    Ritz J, Schlossman SF. 1982. Utilization of monoclonal antibodies in treatment of leukemia and lymphoma. Blood 59:1–11.PubMedGoogle Scholar
  13. 13.
    Ritz J, Pesando JM, Sallan SE, Clavell LA, Notis-McConarty J, Rosenthal P, Schlossman SF. 1981. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58:141–152.PubMedGoogle Scholar
  14. 14.
    Nadler LM, Stashenko P, Hardy R, et al. 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147–3154.PubMedGoogle Scholar
  15. 15.
    Dillman RO, Shawler DL, Sobel RE, et al. 1982. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 59:1036–1045.PubMedGoogle Scholar
  16. 16.
    Dillman RO, Shawler DL, Dillman JB, Royston I. 1984. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881–891.PubMedGoogle Scholar
  17. 17.
    Foon KA, Schroff RW, Bunn PA, et al. 1984. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood, in press.Google Scholar
  18. 18.
    Miller RA, Maloney DG, McKillop J, Levy R. 1981. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58:78–86.PubMedGoogle Scholar
  19. 19.
    Miller RA, Levy R. 1981. Response of cutaneous T cell lymphoma to therapy of hybridoma monoclonal antibody. Lancet 2:225–230.Google Scholar
  20. 20.
    Miller RA, Oseroff AR, Stratte PT, Levy R. 1983. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62:988–995.PubMedGoogle Scholar
  21. 21.
    Foon KA, Schroff RW, Sherwin SA, Oldham RK, Bunn PA, Hsu S-M. 1983. Monoclonal antibody therapy of chronic lymphocytic leukemia and T cell lymphoma: Preliminary observations. In: Monoclonal Antibodies and Cancer. BD Boss, RE Langman, IS Towbridge, R Dulbecco, eds. Academic Press, New York, pp. 39–52.Google Scholar
  22. 22.
    Hatzubai A, Maloney DG, Levy R. 1981. Use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma. J Immunol 126:2397–2402.PubMedGoogle Scholar
  23. 23.
    Miller RA, Maloney DG, Warnke R, Levy R. 1982. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517–522.PubMedCrossRefGoogle Scholar
  24. 24.
    Lowder JN, Meeker TC, Maloney DG, Thielmans K, Miller RA, Levy R. 1984. Anti-idiotype monoclonal antibody therapy of human B lymphocytic malignancy. Proc Am Soc Clin Oncol 3:250.Google Scholar
  25. 25.
    Sklar J, Cleary ML, Thielemans K, Gralow J, Warnke R, Levy R. 1984. Biclonal B-cell lymphoma. N Engl J Med 311:20–27.PubMedCrossRefGoogle Scholar
  26. 26.
    Raffeld M, Cossman J. 1984. Instability of idiotype in follicular lymphomas. Blood (Suppl. 1).Google Scholar
  27. 27.
    Oldham RK, Foon KA, Morgan AC, et al. 1984. Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol, in press.Google Scholar
  28. 28.
    Schroff RW, Farrell MM, Klein RA, Giardina SL, Oldham RK, Foon KA. 1984. T65 antigen modulation in a chronic lymphocytic leukemia phase I monoclonal antibody trial. J Immunol 133:1641–1648.PubMedGoogle Scholar
  29. 29.
    Schroff RW, Foon KA, Wilburn SB, Oldham RK, Morgan AC. 1984. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res, in press.Google Scholar
  30. 30.
    Sears HF, Herlyn D, Steplewski Z, Koprowski H. 1984. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Resp Modif 3:138–150.Google Scholar
  31. 31.
    Foon KA, Bernhard MI, Oldham RK. 1982. Monoclonal antibody therapy: Assessment by animal tumor models. J Biol Resp Modif 1:277–304.Google Scholar
  32. 32.
    Goldenberg DM, DeLand FH. 1982. History and status of tumor imaging with radiolabeled antibodies. J Biol Resp Modif 1:121–136.Google Scholar
  33. 33.
    Goldenberg DM, DeLand FH, Kim EE, et al. 1978. Use of radiolabeled antibody to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 298:1384–1388.PubMedCrossRefGoogle Scholar
  34. 34.
    Mach J-P, Carrel S, Forni M, Ritschard J, Donath A, Alberto P. 1980. Tumor localization of radiolabeled antibodies against carcino-embryonic antigen in patients with carcinoma. N Engl J Med 303:5–10.PubMedCrossRefGoogle Scholar
  35. 35.
    Larsen SM, Carresguillo JA, Krohn KA, et al. 1982. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 72:2101–2114.CrossRefGoogle Scholar
  36. 36.
    Mach J-P, Buchegger F, Forni M, et al. 1981. Use of radiolabeled monoclonal anti-CEA antibodies for detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today, December: 239–249.Google Scholar
  37. 37.
    Epenetos AA, Britton KE, Mather S, et al. 1982. Targeting of mature 123-labeled tumour associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumors. Lancet 2:999–1004.PubMedCrossRefGoogle Scholar
  38. 38.
    Smedley HM, Finan P, Lennox ES, et al. 1983. Localization of metastatic carcinoma by a radiolabeled monoclonal antibody. Br J Cancer 47:253–259.PubMedCrossRefGoogle Scholar
  39. 39.
    Fanands PA, Perkins AC, Pimm MV, et al. 1982. Radio-immunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet 2:397–400.CrossRefGoogle Scholar
  40. 40.
    Order SE, Klein JL, Leichner PK, Wharham MD, Ettinger DS, Siegelman SS. 1982. Advances in iodine 131-labeled antiferritin immunoglobulin cancer therapy. Cancer Bulletin 34: 264–267.Google Scholar
  41. 41.
    Ritz J, Bast RC, Clavell LA, et al. 1982. Autologous bone marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 2:60–63.PubMedCrossRefGoogle Scholar
  42. 42.
    Nadler L, Takvorian T, Botnick L, et al. 1984. Anti-Bl monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin’s lymphoma. Lancet 2:427–431.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Dordrecht 1985

Authors and Affiliations

  • Kenneth A. Foon

There are no affiliations available

Personalised recommendations